Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03980041
Title Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Nivolumab

IPI-549 + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.